149.99

2.21% 3.25

After Hours: 149.99

Repligen Corp (RGEN)

Overview News Price History Option Chain Financials Why RGEN Down? Discussions Forecast

Repligen Corp stock is traded at $149.99, with a volume of 444.05K. It is up +2.21% in the last 24 hours and up +10.73% over the past month. Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Previous Close:

$146.74

Open:

$148.03

24h Volume:

444.05K

Relative Volume:

0.66

Market Cap:

$8.30B

Revenue:

$602.35M

Net Income/Loss:

$-1.90M

P/E Ratio:

73.89

EPS:

2.03

Net Cash Flow:

$119.26M

1W Performance:

+7.98%

1M Performance:

+10.73%

6M Performance:

-5.17%

1Y Performance:

-5.94%

1-Day Range:

$147.30

$150.69

1-Week Range:

$136.54

$150.69

52-Week Range:

$113.50

$211.13

Repligen Corp Stock (RGEN) Company Profile

Name

Repligen Corp

Sector

Healthcare (1200)

Industry

Medical Instruments & Supplies (58)

Phone

(781) 449-9560

Address

41 SEYON STREET, WALTHAM, MA

Employee

1,783

Twitter

@repligen

Next Earnings Date

2024-11-12

Latest SEC Filings

RGEN's Discussions on Twitter

Compare RGEN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RGEN Repligen Corp	149.99	8.30B	602.35M	-1.90M	119.26M	2.03
ISRG Intuitive Surgical Inc	538.55	192.83B	7.87B	2.24B	586.00M	4.25
BDX Becton Dickinson Co	221.98	64.77B	20.18B	1.73B	3.07B	5.51
ALC Alcon Inc	88.23	43.75B	9.76B	1.16B	665.00M	0.72
RMD Resmed Inc	249.33	36.84B	4.81B	1.11B	1.35B	6.16
WST West Pharmaceutical Services Inc	323.32	23.33B	2.88B	499.60M	321.60M	7.41

Repligen Corp Stock (RGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-14-24	Initiated	Wolfe Research	Peer Perform
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-26-24	Upgrade	Deutsche Bank	Hold → Buy
Jun-18-24	Initiated	Guggenheim	Neutral
Dec-04-23	Downgrade	The Benchmark Company	Buy → Hold
Jul-20-23	Initiated	Wells Fargo	Overweight
Jul-05-23	Resumed	JP Morgan	Overweight
Mar-28-23	Initiated	The Benchmark Company	Buy
Dec-14-22	Initiated	Deutsche Bank	Hold
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform
Jul-20-22	Initiated	UBS	Buy
Oct-14-21	Initiated	Exane BNP Paribas	Outperform
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Aug-24-20	Reiterated	H.C. Wainwright	Buy
Jun-30-20	Reiterated	H.C. Wainwright	Buy
May-07-20	Reiterated	H.C. Wainwright	Buy
Mar-23-20	Reiterated	H.C. Wainwright	Buy
Nov-15-19	Initiated	Stifel	Buy
Nov-01-19	Upgrade	First Analysis Sec	Outperform → Strong Buy
Oct-15-19	Initiated	SVB Leerink	Outperform
Aug-28-19	Reiterated	First Analysis Sec	Outperform
Aug-23-19	Resumed	Stephens	Overweight
Jul-22-19	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-17-18	Upgrade	CL King	Neutral → Buy
Nov-12-18	Downgrade	CL King	Buy → Neutral
Sep-26-18	Initiated	H.C. Wainwright	Neutral
Dec-08-17	Initiated	Citigroup	Buy
Dec-05-17	Initiated	JP Morgan	Overweight
Nov-13-17	Initiated	CL King	Buy
Oct-02-17	Upgrade	First Analysis Sec	Equal-Weight → Overweight
Jul-21-17	Initiated	William Blair	Outperform
Feb-13-17	Upgrade	Piper Jaffray	Neutral → Overweight

View All

Repligen Corp Stock (RGEN) Latest News

Nov 25, 2024

Repligen's SWOT analysis: bioprocessing leader faces growth challenges - Investing.com

Nov 25, 2024